Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N -methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the very high failure rate of clinical trials of AD therapeutics (of ~99.6%), many of which were successful in preclinical testing using these animal models [6, 27, 139]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014;Yiannopoulou et al., 2019).”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Cummings et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently approved drugs do little to limit disease progression, and no preventive therapies are available.3,4”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“the success rate of drugs that have gone through clinical trials from 2002 to 2012 show a high failure rate (~ 99.6%) [69]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Efforts to develop drugs to treat Alzheimer’s dementia (AD) have a >99% failure rate”
From Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature (2021) · cites this paper as Cummings et al. 2014
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
Background2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
BackgroundThe International Committee of Medical Journal Editors
van der Weyden, M. (2006) · Proceedings of the Workshop on Publishing for Biomedical Journal Editors and Reviewers · doi:10.2349/biij.2.4.e54-13 · Cited by 1,998
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“economy than cardiovascular disease or cancer [31].”
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · cited 1×
“2014 receptor AD antagonist (memantine) [3,4].”
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
Background
Research works printed but not linked: 4
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2002, Bethesda, MD: US Department of Health and Human Services, Food and Drug Administration
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2004, Bethesda: US Department of Health and Human Services, Food and Drug Administration
- Getz K, Lamberti MJ: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Tufts Cent Study Drug Dev. 2013, 15: 1-4.
- DiMasi JA: Clinical success rates for new cancer drugs double while more enter testing. Tufts Center Study Drug Dev Impact Rep. 2013, 15: 1-4.
Cited by
Items 601–700 of 1,003
Li, W., Dai, S., Liu, J., Wang, Q., Li, G., & Huang, J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150807 · Cited by 31
“a degradation of language function [1, 2].”
Krátký, M., Štěpánková, Š., Vorčáková, K., & Vinšová, J. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.07.004 · Cited by 32
Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer’s Disease
Romeiro, L. A. S., Nunes, J. L. D. C., Miranda, C. D. O., Cardoso, G. S. H. R., de Oliveira, A. S., Gandini, A., Kobrlová, T., Soukup, O., Rossi, M., Senger, J., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00071 · Cited by 37
McRae‐McKee, K., Evans, S., Hadjichrysanthou, C., Wong, M. M., de Wolf, F., & Anderson, R. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-42632-w · Cited by 35
Development of the “hidden” multifunctional agents for Alzheimer's disease
Huang, W., Liang, M., Li, Q., Zheng, X., Zhang, C., Wang, Q., Tang, L., Zhang, Z., Wang, B., & Shen, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.051 · Cited by 31
Comprehensive analysis of PM20D1 QTL in Alzheimer’s disease
Sanchez-Mut, J. V., Glauser, L., Monk, D., & Gräff, J. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-0814-y · Cited by 42
An Overview of Astrocyte Responses in Genetically Induced Alzheimer’s Disease Mouse Models
Spanos, F., & Liddelow, S. A. (2020) · Cells · doi:10.3390/cells9112415 · Cited by 34
“humans that are designed to inhibit Aβ production, its aggregation, or to enhance its clearance from the brain, and which effectively treat AD [6,7].”
BackgroundDeRidder, L. B., Sharma, A., Liaw, K., Sharma, R. B., John, J., Kannan, S., & Kannan, R. M. (2021) · Nanoscale · doi:10.1039/d0nr05958g · Cited by 33
Value-Generating Exploratory Trials in Neurodegenerative Dementias
Friedman, L. G., McKeehan, N., Hara, Y., Cummings, J. L., Matthews, D. C., Zhu, J., Mohs, R. C., Wang, D., Hendrix, S. B., Quintana, M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011774 · Cited by 34
“The key recommendations for executing this approach include (1) leveraging rigorous statistical analyses/procedures and statisticians’ expertise, (2) incorporating the appropriate endpoints (biomarker and clinical) that reflect the drug mechanism of action and specific study population, (3) leveraging historical data…”
MethodSelf-citationDorababu, A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174847 · Cited by 32
An Update on Treatment of Cognitive Impairment Associated with Schizophrenia
Horan, W. P., Catalano, L. T., & Green, M. F. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_382 · Cited by 35
APP Overexpression Causes Aβ-Independent Neuronal Death through Intrinsic Apoptosis Pathway
Cheng, N., Jiao, S., Gumaste, A., Bai, L., & Belluscio, L. (2016) · eNeuro · doi:10.1523/eneuro.0150-16.2016 · Cited by 31
“Unfortunately, therapeutic development based on this approach either through antibody-based clearance of A (Doody et al., 2014; Salloway et al., 2014) or supressing A production by interfering with BACE1 or -secretase activity (Green et al., 2009; Ghosh et al., 2012; Doody et al., 2013), has…”
BackgroundAustin, J., Hollingshead, K., & Kaye, J. A. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.7671 · Cited by 34
“However, from 2002-2012, the clinical trial success of AD drugs advancing to market was 1 out of 244 tested compounds [2], leading some to call this AD’s “lost decade” [3].”
Arnerić, S. P., Kern, V. D., & Stephenson, D. T. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.043 · Cited by 37
Rajeshwari, R., Chand, K., Candeias, E., Cardoso, S. M., Chaves, S., & Santos, M. A. (2019) · Molecules · doi:10.3390/molecules24030587 · Cited by 31
“However, these are just symptomatic drugs, as they can only lead to temporary amelioration of memory and cognitive problems, and so, unfortunately, they do not interfere with the course of the disease [3].”
BackgroundMarshall, L. J., Constantino, H., & Seidle, T. (2022) · Animals · doi:10.3390/ani12070863 · Cited by 38
“Alzheimer’s disease [32], yet the treatment options remain extremely limited, with either high costs [33] or adverse side effects [34], proving disadvantageous to patients and carers.”
BackgroundApproaches for discovering anti-prion compounds: lessons learned and challenges ahead
Bolognesi, M. L., & Legname, G. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1016498 · Cited by 30
“This is among the lowest for any therapeutic area [7].”
BackgroundAlzheimer's disease: cost cuts call for novel drugs development and national strategy
Marešová, P., Klímová, B., & Kuča, K. (2015) · Česká a slovenská farmacie · doi:10.36290/csf.2015.005 · Cited by 31
Chaves, S., Hiremathad, A., Tomás, D., Keri, R. S., Piemontese, L., & Santos, M. A. (2018) · New Journal of Chemistry · doi:10.1039/c8nj00117k · Cited by 30
A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation
Kim, S. H., Noh, M. Y., Kim, H.-J., Oh, K.-W., Park, J., Lee, S., Moon, Y., Kim, Y.-E., Bae, J. S., Jin, H. K., et al. (2019) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2019.18.2.33 · Cited by 30
Wang, Z.-J., Zhao, F., Wang, C.-F., Zhang, X., Xiao, Y., Zhou, F., Wu, M., Zhang, J., Qi, J., & Yang, W. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190796 · Cited by 30
de Sá, R. V., Luna, M. C., & Pasterkamp, R. J. (2021) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2020.0337 · Cited by 33
Wang, Y., Jiang, J., Fu, X., Zhang, J., Song, J., Wang, Y., Duan, L., Shao, P., Xu, X., Zeng, L., et al. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102507 · Cited by 38
Memantine Extended Release (28 mg Once Daily): A Review of Its Use in Alzheimer’s Disease
Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0400-3 · Cited by 32
“Pharmacological treatment options in Alzheimer’s disease include cholinesterase inhibitors and memantine, although research in the development of new agents is ongoing [4].”
BackgroundRiedel, G., Klein, J., Niewiadomska, G., Kondak, C., Schwab, K., Lauer, D., Magbagbeolu, M., Steczkowska, M., Zadrożny, M., Wydrych, M., et al. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200224120926 · Cited by 31
Dementia clinical trials over the past decade: are women fairly represented?
Pinho‐Gomes, A., Gong, J., Harris, K., Woodward, M., & Carcel, C. (2022) · BMJ Neurology Open · doi:10.1136/bmjno-2021-000261 · Cited by 33
Beyond Vision: A View from Eye to Alzheimer's Disease and Dementia
Zheng, C., Zeng, R., Wu, G., Hu, Y., & Yu, H. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.118 · Cited by 30
“Additionally, many clinical trials have been undertaken and some promising agents, such as lecanemab and donanemab, were supposed to contribute to slowing the cognition decline in patients with early symptomatic AD (88-91).”
Omar, M. A., El‐Shiekh, R. A., Dawood, D. H., Temirak, A., & Srour, A. M. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0238 · Cited by 33
Kamath, A. P., Nayak, P. G., John, J., Mutalik, S., Balaraman, A. K., & Nandakumar, K. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110096 · Cited by 37
Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer’s disease
Initiative, F. T. A. D. N., Ower, A. K., Hadjichrysanthou, C., Gras, L., Goudsmit, J., Anderson, R. M., & de Wolf, F. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-017-0326-z · Cited by 29
Amylin in Alzheimer's disease: Pathological peptide or potential treatment?
Mietlicki‐Baase, E. G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.016 · Cited by 31
Unravelling protein aggregation as an ageing related process or a neuropathological response
Trigo, D., Nadais, A., & Silva, O. A. B. D. C. E. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.02.001 · Cited by 34
Chen, G., Yang, K. Y., Du, W., Hu, X., & Han, Y. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190501 · Cited by 30
Rao, C. V., Farooqui, M., Madhavaram, A., Zhang, Y., Asch, A. S., & Yamada, H. Y. (2020) · Aging Cell · doi:10.1111/acel.13221 · Cited by 29
Lee, P., Kim, H.-R., Jeong, Y., & Initiative, F. T. A. D. N. (2020) · BMC Neurology · doi:10.1186/s12883-020-01939-2 · Cited by 29
Optical Coherence Tomography in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis
Mejia-Vergara, A. J., Restrepo-Jiménez, P., & Pelak, V. S. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.578698 · Cited by 35
MacDougall, G., Brown, L. Y., Kantor, B., & Chiba‐Falek, O. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.001 · Cited by 33
Hua, X., Church, K. J., Walker, W., L’Hostis, P., Viardot, G., Danjou, P., Hendrix, S., & Moebius, H. J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215511 · Cited by 34
Bhattacharjee, R., Jana, A., Nandi, A., Sinha, A., Bhattacharjee, A., Mitra, S., Kar, S., Dey, A., Singh, S. K., Varma, R. S., et al. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.111415 · Cited by 31
Wu, X., Kosaraju, J., Zhou, W., & Tam, K. Y. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00388 · Cited by 28
Pang, X., Fu, H. Z., Yang, S., Wang, L., Liu, A., Wu, S., & Du, G. (2017) · Molecules · doi:10.3390/molecules22081254 · Cited by 31
“At present, four cholinesterase inhibitors (tacrine, donepezil, rivastigmine, and galantamine) were approved for the treatment of AD [11].”
BackgroundBott, N. T., Kumar, S., Krebs, C., Glenn, J. M., Madero, E. N., & Juusola, J. L. (2018) · JMIR Research Protocols · doi:10.2196/11368 · Cited by 34
“compounds [3], leading some major pharmaceutical companies to abandon research efforts in the face of continued failures.”
BackgroundThe involvement of microglia in Alzheimer's disease: a new dog in the fight
Moore, Z., Taylor, J. M., & Crack, P. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14546 · Cited by 29
Yeo-Teh, N. S. L., & Tang, B. L. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-022-00422-0 · Cited by 28
“However, despite intensive efforts in the therapeutics development, the disease has had no effective disease-modifying treatment (Cummings et al., 2014).”
BackgroundRecommendations toward a human pathway-based approach to disease research
Marshall, L. J., Austin, C. P., Casey, W., Fitzpatrick, S. C., & Willett, C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.038 · Cited by 28
Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies
Golde, T. E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13583 · Cited by 29
Махаева, Г. Ф., Sokolov, V. B., Shevtsova, E. F., Ковалева, Н. В., Lushchekina, S. V., Boltneva, N. P., Рудакова, Е. В., Aksinenko, A. Y., Shevtsov, P. N., Неганова, М. Е., et al. (2017) · Pure and Applied Chemistry · doi:10.1515/pac-2017-0308 · Cited by 29
Meng, G., & Mei, H. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00101 · Cited by 28
“As the population ages, AD will impact more people and place an increasing economic burden on society (Cummings et al., 2014; Alzheimer’s, 2015).”
BackgroundCaneus, J., Akanda, N., Rumsey, J. W., Guo, X., Jackson, M., Long, C. J., Sommerhage, F., Georgieva, S., Kanaan, N. M., Morgan, D., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12029 · Cited by 33
Moving drug discoveries beyond the valley of death: the role of innovation ecosystems
Calza, F., Ferretti, M., Panetti, E., & Parmentola, A. (2020) · European Journal of Innovation Management · doi:10.1108/ejim-11-2019-0342 · Cited by 41
Stoye, N. M., Guilherme, M. D. S., & Endres, K. (2020) · The FASEB Journal · doi:10.1096/fj.201903128rr · Cited by 31
Multifunctional nano-enabled delivery systems in Alzheimer's disease management
Qian, C., Yuan, C., Li, C., Liu, H., & Wang, X. (2020) · Biomaterials Science · doi:10.1039/d0bm00756k · Cited by 28
Wearn, A. R., Nurdal, V., Saunders-Jennings, E., Knight, M. J., Isotalus, H., Dillon, S., Tsivos, D., Kauppinen, R. A., & Coulthard, E. J. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00672-9 · Cited by 36
Xu, M., Zhou, M., Li, S., Zhen, X., & Yang, S. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24805 · Cited by 29
“This may be due to the lack of understanding of pathogenesis and relatively late treatments (Cummings et al., 2014; Liu et al., 2019; Merchant et al., 2019).”
BackgroundAssociation between exenatide use and incidence of Alzheimer's disease
Zhou, B., Zissimopoulos, J., Nadeem, H., Crane, M. A., Goldman, D. P., & Romley, J. A. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12139 · Cited by 33
What Can Economics Say about Alzheimer’s Disease?
Chandra, A., Coile, C., & Mommaerts, C. (2023) · Journal of Economic Literature · doi:10.1257/jel.20211660 · Cited by 37
Behavioral Interventions in Mild Cognitive Impairment (MCI): Lessons from a Multicomponent Program
Levy, S.-A. T., Smith, G. E., Wit, L. D., DeFeis, B. L., Ying, G., Amofa, P., Locke, D. E. C., Shandera‐Ochsner, A. L., McAlister, C. B., Phatak, V. S., et al. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01225-8 · Cited by 37
Saleem, S., Banerjee, R., & Kannan, R. R. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00240 · Cited by 30
Spinelli, G., on behalf of the INSIGHT-preAD Study Group, Bakardjian, H., Schwartz, D., Potier, M., Habert, M., Lévy, M., Dubois, B., & George, N. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220204 · Cited by 34
Zhang, P., Hou, Y., Tu, W., Campbell, N. L., Pieper, A. A., Leverenz, J. B., Gao, S., Cummings, J. L., & Cheng, F. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12819 · Cited by 32
Self-citationIdentification of key regions and residues controlling Aβ folding and assembly
Hayden, E. Y., Hoi, K. K., Lopez, J., Inayathullah, M., Condron, M. M., & Teplow, D. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-10845-6 · Cited by 30
Cuberas‐Borrós, G., Roca, I., Boada, M., Tárraga, L., Hernández, I., Buendía, M., Rubio, L., Torres, G., Bittini, A., Guzmán‐De‐Villoria, J. A., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170693 · Cited by 29
Bennett, D. A. (2018) · JAMA · doi:10.1001/jama.2017.19700 · Cited by 33
Asiatic acid and its derivatives: Pharmacological insights and applications
Liang, C., Ma, Y., Ding, M., Gao, F., Yu, K., Wang, S., Qu, Y., Hu, X., & Li, D. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117429 · Cited by 33
Impaired Reversal Learning in APPPS1-21 Mice in the Touchscreen Visual Discrimination Task
den Broeck, L. V., Hansquine, P., Callaerts‐Vegh, Z., & D’Hooge, R. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00092 · Cited by 31
Maříková, J., Ritomská, A., Korábečný, J., Peřinová, R., Mamun, A. A., Kučera, T., Kohelová, E., Hulcová, D., Kobrlová, T., Kuneš, J., et al. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00561 · Cited by 28
Targeting Pathological Tau by Small Molecule Inhibition of the Poly(A):MSUT2 RNA–Protein Interaction
Baker, J. D., Uhrich, R. L., Strovas, T. J., Saxton, A. D., & Kraemer, B. C. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00214 · Cited by 26
Guo, S., Li, K., Chen, Y., & Li, B. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.007 · Cited by 27
Ezzati, A., Abdulkadir, A., Jack, C. R., Thompson, P. M., Harvey, D. J., Truelove‐Hill, M., Sreepada, L. P., Davatzikos, C. A., Initiative, T. A. D. N., & Lipton, R. B. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12491 · Cited by 28
Kaur, H., Chahal, S., Jha, P., Lekhak, M. M., Shekhawat, M. S., Naidoo, D., Arencibia, A. D., Ochatt, S., & Kumar, V. (2022) · Plant Cell Tissue and Organ Culture (PCTOC) · doi:10.1007/s11240-022-02229-0 · Cited by 31
Prevention of Alzheimer's disease through diet: An exploratory review
Bhuiyan, N. Z., Hasan, M. K., Mahmud, Z., Hossain, M. S., & Rahman, A. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100257 · Cited by 37
“…many recent studies have shown that targeting drug treatment to some biomarkers (which are also called secondary prevention), such as tau protein and Beta-Amyloid, which are also believed to have a critical role in Alz-heimer ’ s pathogenesis, did not show any positive feedback so far [7 – 10].”
BackgroundCholinesterase inhibitory activity of chlorophenoxy derivatives—Histamine H3 receptor ligands
Łażewska, D., Jończyk, J., Bajda, M., Szałaj, N., Więckowska, A., Panek, D., Moore, C., Kuder, K., Malawska, B., & Kieć‐Kononowicz, K. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.054 · Cited by 27
Tolerability of ORM‐12741 and effects on episodic memory in patients with Alzheimer's disease
Rinne, J. O., Wesnes, K. A., Cummings, J. L., Hakulinen, P., Hallikainen, M., Hänninen, J., Murphy, M. F., Riordan, H., Scheinin, M., Soininen, H. S., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.11.004 · Cited by 29
“According to a recent analysis of the AD drug development pipeline, there were 24 compounds in phase 3 and 45 compounds in phase 2 clinical trials [4].”
MethodSelf-citationPotential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer’s Disease
Drummond, E., Goñi, F., Liu, S., Prelli, F., Scholtzova, H., & Wısnıewskı, T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179909 · Cited by 27
“…premature translation of successful pathology reduction in transgenic (Tg) mouse models, which have pathology driven by over-expression of very rare EOAD mutations, to humans withsADinwhomthepathologyisdrivenbysubstan-tiallydifferentpathways,whichmayvaryinimpor-tancefrompatienttopatient[3,31–33].”
Multi-targeted ChEI-copper chelating molecules as neuroprotective agents
Sestito, S., Wang, S., Chen, Q., Lu, J., Bertini, S., Pomelli, C. S., Chiellini, G., He, X., Pi, R., & Rapposelli, S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.060 · Cited by 27
Magnetoencephalography applied to the study of Alzheimer's disease
López‐Sanz, D., Bruña, R., de Frutos‐Lucas, J., & Maestú, F. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.04.007 · Cited by 31
Qiu, R., Ahn, J. E., Alexander, R., Brodney, M. A., He, P., Leurent, C., Mancuso, J., Margolin, R. A., Tankisheva, E., & Chen, D. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190228 · Cited by 27
“Current approved therapies, including cholinesterase inhibitors and an N-methyl-D-aspartate-receptor antagonist, provide symptomatic improvement but do not affect the progression of the disease [3, 4].”
BackgroundBell, S., Marco, M. D., Barnes, K., Shaw, P. J., Ferraiuolo, L., Blackburn, D. J., Mortiboys, H., & Venneri, A. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10020032 · Cited by 31
“Strategies aimed at reducing the amyloid load in the brain, however, have failed to control the disease [6] and have resulted in a large number of clinical trials that have failed to achieve primary outcome measures [7].”
BackgroundSantos, G. S., Sinoti, S. B. P., de Almeida, F. T. C., Silveira, D., Simeoni, L. A., & Gomes-Copeland, K. K. P. (2020) · Plant Cell Tissue and Organ Culture (PCTOC) · doi:10.1007/s11240-020-01911-5 · Cited by 28
Global Energy Metabolism Deficit in Alzheimer Disease Brain
Patel, V., Mill, J. S., Okonkwo, O. C., Salamat, S. M., Li, L., & Raife, T. J. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.91 · Cited by 28
“Perhaps the strongest evidence of the limitations of the amyloid hypothesis is the lack of success in clinical trials of amyloid-targeting treatments (8).”
Dan, L., Hao, Y., Li, J., Wang, T., Zhao, W., Wang, H., Qiao, L., & Xie, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1287750 · Cited by 31
Beyond amyloid and tau: rethinking Alzheimer’s disease through less explored avenues
Gyimesi, M., Okolicsanyi, R. K., & Haupt, L. M. (2024) · Open Biology · doi:10.1098/rsob.240035 · Cited by 33
“Despite extensive research dedicated to understanding the formation and regulation of APP and Aβ peptides, the limited success observed to date in clinical trials using anti-Aβ therapies suggests Aβ may not be the primary pathogenic factor in AD [7].”
BackgroundLiu, B., Chen, X., Li, Y., Liu, H., Guo, S., & Yu, P. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s174756 · Cited by 26
“The cause of dementia remains unclear, nor is there any specific and effective cure for it thus far.(2) Therefore, it is recommended to focus its nursing intervention on activities that can delay disease progression and promote quality-of-life.”
Desai, R. J., Varma, V. R., Gerhard, T., Segal, J., Mahesri, M., Chin, K., Nonnenmacher, E., Gabbeta, A., Mammen, A. M., Varma, S., et al. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12095 · Cited by 27
Jian, C., Wei, L., Mo, R., Li, R., Liang, L., Chen, L., Zou, C., Meng, Y., Liu, Y., & Zou, D. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.731180 · Cited by 29
Review on the roles of specific cell-derived exosomes in Alzheimer's disease
Zou, Y., Mu, D., Ma, X., Wang, D., Zhong, J., Gao, J., Yu, S., & Qiu, L. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.936760 · Cited by 33
Hsieh, Y., Negri, J. M., He, A., Pearse, R. V., Liu, L., Duong, D. M., Chibnik, L. B., Bennett, D. A., Seyfried, N. T., & Young‐Pearse, T. L. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00558-4 · Cited by 27
“Background Alzheimer’s Disease (AD) is the most common cause of age-related dementia and its prevalence is expected to grow in the coming years, with estimates as high as 100 million sufferers worldwide by 2050 [1].”
BackgroundStrefeler, A., Jan, M., Quadroni, M., Teav, T., Rosenberg, N., Chatton, J., Guex, N., Gallart‐Ayala, H., & Ivanišević, J. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01162-4 · Cited by 27
Anti-amyloid: An antibody to cure Alzheimer’s or an attitude
Osborne, O., Naranjo, O., Heckmann, B. L., Dykxhoorn, D. M., & Toborek, M. J. (2023) · iScience · doi:10.1016/j.isci.2023.107461 · Cited by 26
Multimedia Aided Consent for Alzheimer’s Disease Research
Palmer, B. W., Harmell, A. L., Dunn, L. B., Kim, S. Y. H., Pinto, L. L., Golshan, S., & Jeste, D. V. (2017) · Clinical Gerontologist · doi:10.1080/07317115.2017.1373177 · Cited by 29
“…were distinct, thus representing an internal replication, and were designed to be ecologically valid, in that cholinomimetic and amyloid clearance compounds currently represent common avenues of AD clinical research (Cummings et al., 2014; Ferreira-Vieira, Guimaraes, Silva, & Ribeiro, 2016).”
BackgroundPast to Future: What Animal Models Have Taught Us About Alzheimer’s Disease
Martini, A. C., Forner, S., Trujillo‐Estrada, L., Baglietto‐Vargas, D., & LaFerla, F. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179917 · Cited by 29
“Currently there are over 100 trials and about 80 drugs in the pipeline, and 99.6% of clinical trials have failed to translate into approved treatments [92, 93].”
InfluentialGe, M., Zhang, Y., Hao, Q., Zhao, Y., & Dong, B. (2018) · Brain and Behavior · doi:10.1002/brb3.982 · Cited by 27
Tasaki, S., Gaiteri, C., Mostafavi, S., Yu, L., Wang, Y., Jager, P. L. D., & Bennett, D. A. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00294 · Cited by 30
“The repeated failure of traditional drug discoveries for Alzheimer’s dementia (AD) (Cummings et al., 2014; Gauthier et al., 2016) indicate the necessity of a paradigm shift toward precision medicine that aims to perturb the right targets in specific people at the right time (Collins and Varmus, 2015).”
BackgroundCan cloud-based tools accelerate Alzheimer’s disease drug discovery?
Cacabelos, R., Teijido, Ó., & Carril, J. C. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1141892 · Cited by 26
Präventionsstrategien gegen Demenz
Müller, P., Schmicker, M., & Müller, N. G. (2017) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-017-1202-x · Cited by 25
“Eine Markteinführung von Medikamenten, die kausal in das Krankheitsgeschehen eingreifenundden Krankheitsverlauf relevant modifizieren können, ist derzeit nicht absehbar [11].”
Human Glial Cells as Innovative Targets for the Therapy of Central Nervous System Pathologies
Magni, G., Riboldi, B., & Ceruti, S. (2024) · Cells · doi:10.3390/cells13070606 · Cited by 30
“Suffice it to say that drug candidates for AD have a failure rate around 99.6% in clinical trials [88].”
BackgroundInfluentialETHICAL ISSUES IN THE DEVELOPMENT OF READINESS COHORTS IN ALZHEIMER’S DISEASE RESEARCH
Milne, R., Bunnik, E. M., Tromp, K., Bemelmans, S. A. S. A., Badger, S. J., Gove, D., Maman, M., Schermer, M., Truyen, L., Brayne, C., et al. (2017) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2017.5 · Cited by 28
“This failure has been attributed in part to the choice of study population (1, 2): while the majority of past research has focused on patients with mild-to-moderate Alzheimer’s dementia, recent clinical trials have begun to concentrate on the earlier stages of the disease identified by revised research diagnostic crit…”
BackgroundVérité, J., Janet, T., Chassaing, D., Fauconneau, B., Rabeony, H., & Page, G. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1220-7 · Cited by 26
Tackling gaps in developing life‐changing treatments for dementia
Mauricio, R., Benn, C., Davis, J. B., Dawson, G. R., Dawson, L. A., Evans, A., Fox, N. C., Gallacher, J., Hutton, M., Isaac, J. T. R., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.001 · Cited by 31
“The number of compounds that progress to regulatory review is among the lowest for any therapeutic area [42].”
BackgroundPiemontese, L., Sergio, R., Rinaldo, F., Brunetti, L., Perna, F. M., Santos, M. A., & Capriati, V. (2020) · Molecules · doi:10.3390/molecules25030574 · Cited by 28
Metadata
- Authors
- Cummings, J. L., Morstorf, T., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Touro University Nevada (US)
- Corresponding author
- Cummings, Jeffrey L
- Venue
- Alzheimer's Research & Therapy
- Published
- 2014-07-03
- Volume
- 6
- Issue
- 4
- Pages
- 37-37
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC4095696
- OpenAlex
- W2146249493
- Cited by
- 1,744
- References
- 29
- Citations by year
- 2026: 86 · 2025: 65 · 2024: 113 · 2023: 122 · 2022: 189 · 2021: 193 · 2020: 208 · 2019: 207 · 2018: 200 · 2017: 144 · 2016: 122 · 2015: 79 · 2014: 15
- FWCI
- 79.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, trial attrition, disease-modifying therapy, immunotherapy, cholinesterase inhibitors, NMDA receptor antagonists, ClinicalTrials.gov, pharmaceutical industry sponsorship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
